STOCK TITAN

Balyasny funds disclose 6.18% Verastem (VSTM) stake via shares and warrants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Balyasny Asset Management and affiliates report a 6.18% beneficial stake in Verastem Inc. common stock. The group reports beneficial ownership of 4,767,154 shares, consisting of 3,195,726 shares and 1,571,428 shares issuable upon exercise of warrants that are subject to a 9.99% beneficial ownership blocker.

The percentage is based on 77,154,709 Verastem shares outstanding as of November 17, 2025. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Verastem.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Balyasny Asset Management L.P.
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:02/12/2026
BAM GP LLC
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:02/12/2026
Balyasny Asset Management Holdings LP
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:02/12/2026
Dames GP LLC
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:02/12/2026
Dmitry Balyasny
Signature:/s/ Dmitry Balyasny
Name/Title:Dmitry Balyasny / Self
Date:02/12/2026

FAQ

What stake in Verastem Inc. (VSTM) does Balyasny report in this Schedule 13G/A?

Balyasny and related entities report beneficial ownership of 4,767,154 Verastem shares, or about 6.18% of the common stock. This includes both currently held shares and shares issuable upon exercise of warrants, subject to ownership limits.

How is Balyasny’s 6.18% Verastem (VSTM) ownership stake calculated?

The 6.18% ownership is based on 77,154,709 Verastem shares outstanding as of November 17, 2025. Balyasny’s reported 4,767,154 shares, including warrant shares, is divided by that outstanding share count disclosed in Verastem’s November 17, 2025 prospectus.

What securities make up Balyasny’s Verastem (VSTM) position in this filing?

The reported position consists of 3,195,726 Verastem common shares and 1,571,428 additional shares issuable upon exercise of warrants. The warrants are subject to a 9.99% beneficial ownership limitation, which restricts exercises that would push ownership above that threshold.

Does Balyasny’s Verastem (VSTM) filing indicate an attempt to influence control?

No. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Verastem, nor in connection with any transaction having that control-related purpose or effect.

Who directly holds the Verastem (VSTM) shares reported by Balyasny?

The filing explains that Atlas Diversified Master Fund, Ltd. (ADMF) directly holds the Verastem securities. Balyasny Asset Management L.P. acts as investment manager to ADMF and, along with related entities and Dmitry Balyasny, is deemed to share beneficial ownership and voting power.

What voting and dispositive power does Balyasny report over Verastem (VSTM) shares?

Each reporting person discloses sole voting power and sole dispositive power over 4,767,154 Verastem shares, with no shared voting or dispositive power. This reflects their control over how the ADMF-held position is voted and potentially sold.

What is the significance of the 9.99% beneficial ownership limitation on Verastem warrants?

The warrants include a 9.99% beneficial ownership limitation, preventing exercises that would push the holder’s beneficial ownership above 9.99% of outstanding shares. This contractual blocker caps how many warrant shares can be exercised at any time, constraining the maximum reportable stake.
Verastem

NASDAQ:VSTM

VSTM Rankings

VSTM Latest News

VSTM Latest SEC Filings

VSTM Stock Data

438.36M
11.68M
Biotechnology
Pharmaceutical Preparations
Link
United States
NEEDHAM